Clovis Oncology

Clovis Oncology ( CLVS) is engaged in acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. This stock closed up 16.68% at $54.56 in Wednesday's trading session.

Wednesday's Volume: 1.12 million
Three-Month Average Volume: 443,143
Volume % Change: 130% P/> >>5 Big Stocks to Trade Big Gains

From a technical perspective, CLVS skyrocketed higher here back above its 200-day moving average of $50.95 with above-average volume. This move pushed shares of CLVS into breakout territory, since the stock took out some near-term overhead resistance at $53.35. Shares of CLVS are now quickly moving within range of triggering another big breakout trade. That trade will hit if CLVS manages to take out Wednesday's high of $54.97 to its 50-day moving average of $56.82 with high volume.

Traders should now look for long-biased trades in CLVS as long as it's trending above its 200-day at $50.95 and then once it sustains a move or close above those breakout levels with volume that hits near or above 443,143 shares. If that breakout hits soon, then CLVS will set up to re-test or possibly take out its next major overhead resistance levels at $64 to $65.

Biomarin Pharmaceutical

Biomarin Pharmaceutical ( BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions. This stock closed up 3.3% at $69.14 in Wednesday's trading session.

Wednesday's Volume: 4.40 million
Three-Month Average Volume: 1.88 million
Volume % Change: 107%

From a technical perspective, BMRN spiked higher here right off its 50-day moving average of $68.62 with strong upside volume. This stock has been uptrending strong for the last few weeks, with shares moving higher from its low of $58.65 to its intraday high of $71.76. During that move, shares of BMRN have been consistently making higher lows and higher highs, which is bullish technical price action. Market players should now look for a continuation move higher in the short-term if BMRN can take out Wednesday's high of $71.76 with strong volume.

Traders should now look for long-biased trades in BMRN as long as it's trending above its 50-day at $68.62 or above $67.50 and then once it sustains a move or close above $71.76 with volume that this near or above 1.88 million shares. If we get that move soon, then BMRN will set up to re-test or possibly take out its next major overhead resistance levels at $76 to its 52-week high at $80.67.

ANI Pharmaceuticals

ANI Pharmaceuticals ( ANIP) is a specialty pharmaceutical company engaged in the development of products for female sexual health, menopause, contraception and male hypogonadism. This stock closed up 6.8% at $13.45 in Wednesday's trading session.

Wednesday's Volume: 125,000
Three-Month Average Volume: 64,660
Volume % Change: 106%

From a technical perspective, ANIP spiked sharply higher here into new 52-week high territory with strong upside volume. This stock has been uptrending strong for the last two months and change, with shares moving higher from its low of $6.84 to its intraday high of $13.49. During that uptrend, shares of ANIP have been making mostly higher lows and higher highs, which is bullish technical price action.

Traders should now look for long-biased trades in ANIP as long as it's trending above its recent breakout level of $12 and then once it sustains a move or close above its new 52-week high at $13.49 with volume that's near or above 64,660 shares. If we get that move soon, then ANIP will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $17 to $20.

To see more stocks rising on unusual volume, check out the Stocks Rising on Unusual Volume portfolio on Stockpickr.

-- Written by Roberto Pedone in Delafield, Wis.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Delafield, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half